Azaindole inhibitors of wild-type and mutant forms of LRRK2
US12275731B2 · kind B2 · utility
0Cited by
0References
20Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Oct 16, 2019 |
| Grant date | Apr 15, 2025 |
| Priority date | — |
| Expiry date | Apr 21, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/16
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are compounds that possess inhibitory activity against LRRK2. Also disclosed are pharmaceutical compositions containing the compounds and methods of using the compounds to treat diseases and disorders including neurodegenerative diseases and disorders such as Parkinson's disease, and brain cancer (e.g., gliomas and glioblastomas).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.